Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive NBI-1065845 in Adults With Major Depressive Disorder
2021-003989-12Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing NBI-1065845 + oral antidepressant with Placebo + oral antidepressant (2 arms). Primary endpoint: Change from Baseline in Total MADRS Score at Day 28. Started Dec 2021; status: completed.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2021-003989-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003989-12.